https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-06 / Cancers (Basel) 2020 Mar;12(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-06 / Cancers (Basel) 2020 Mar;12(3)2020-03-06 00:00:002020-03-06 00:00:00Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-772020-02-21 00:00:002020-02-21 00:00:00[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-09 / Neoplasma 2020 May;67(3):677-683
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-09 / Neoplasma 2020 May;67(3):677-6832020-02-09 00:00:002020-02-09 00:00:00Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-01 / Integr Cancer Ther 2020 Jan-Dec;19:1534735420932648
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-01 / Integr Cancer Ther 2020 Jan-Dec;19:15347354209326482020-01-01 00:00:002020-01-01 00:00:00A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-01 / Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820963599
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-01 / Technol Cancer Res Treat 2020 Jan-Dec;19:15330338209635992020-01-01 00:00:002020-01-01 00:00:00Efficacy of Combination Neoadjuvant Chemotherapy and Regional Inductive Moderate Hyperthermia in the Treatment of Patients With Locally Advanced Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-01 / Int J Hyperthermia 2020;37(1):711-741
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-01 / Int J Hyperthermia 2020;37(1):711-7412020-01-01 00:00:002020-01-01 00:00:00Heating technology for malignant tumors: a review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Front Oncol 2019;9:1012
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Front Oncol 2019;9:10122019-11-01 00:00:002021-05-12 07:14:18Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-838
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-8382019-09-01 00:00:002020-08-26 14:25:47Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-08-17 / Int J Mol Sci 2019 Aug;20(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-08-17 / Int J Mol Sci 2019 Aug;20(16)2019-08-17 00:00:002019-08-17 00:00:00Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-19 / PLoS ONE 2019;14(6):e0217894
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-19 / PLoS ONE 2019;14(6):e02178942019-06-19 00:00:002019-06-19 00:00:00The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial
